A phase I/II clinical trial of a TCR therapy recognising a naturally processed peptide shared by the cancer/testis antigens NY-ESO-1 and LAGE-1, was conducted in 20 antigen-positive MM patients with results published in 2015 by Rapoport et al. [126]. Here, CTAG2 is linked to Miyoshi myopathy.